BeiGene Ltd. Market Cap ($25.73 Billion)
Market Cap & Net Worth: BeiGene Ltd. (49B)
BeiGene Ltd. market cap. BeiGene Ltd. (F:49B) has a market capitalization of $25.73 Billion (€22.01 Billion) as of October 31, 2026. Listed on the F stock exchange, this Germany-based company holds position #1032 globally and #232 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BeiGene Ltd.'s stock price €17.34 by its total outstanding shares 1291260032 (1.29 Billion).
BeiGene Ltd. Market Cap History (2018–2025)
BeiGene Ltd. market cap history from 2018 to 2025. Data shows growth from $13.69 Billion to $26.17 Billion (6.85% CAGR). Check BeiGene Ltd. (49B) share price today for real-time trading data and today's change.
BeiGene Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BeiGene Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash flow conversion of BeiGene Ltd. for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
5.23x
BeiGene Ltd.'s market cap is 5.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $13.69 Billion | $198.22 Million | -$673.77 Million | 69.08x | N/A |
| 2019 | $17.21 Billion | $428.21 Million | -$948.63 Million | 40.19x | N/A |
| 2020 | $23.25 Billion | $308.87 Million | -$1.60 Billion | 75.27x | N/A |
| 2021 | $25.91 Billion | $1.18 Billion | -$1.41 Billion | 22.02x | N/A |
| 2022 | $23.87 Billion | $1.42 Billion | -$2.00 Billion | 16.86x | N/A |
| 2023 | $18.72 Billion | $2.46 Billion | -$881.71 Million | 7.61x | N/A |
| 2024 | $19.93 Billion | $3.81 Billion | -$644.79 Million | 5.23x | N/A |
Competitor Companies of 49B by Market Capitalization
Companies near BeiGene Ltd. in the global market cap rankings as of October 31, 2026. See BeiGene Ltd. balance sheet quality to understand what proportion of total assets are financed by equity.
Key companies related to BeiGene Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of BeiGene Ltd. (2018–2025)
Market capitalization of BeiGene Ltd. from 2018 to today. Between 2018 and today, BeiGene Ltd.'s market cap moved from $13.69 Billion to $ 26.17 Billion, with a yearly change of 6.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €26.17 Billion | +31.33% |
| 2024 | €19.93 Billion | +6.45% |
| 2023 | €18.72 Billion | -21.59% |
| 2022 | €23.87 Billion | -7.84% |
| 2021 | €25.91 Billion | +11.43% |
| 2020 | €23.25 Billion | +35.09% |
| 2019 | €17.21 Billion | +25.69% |
| 2018 | €13.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 8th, 2026 the market cap of BeiGene Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $25.73 Billion USD |
| MoneyControl | $25.73 Billion USD |
| MarketWatch | $25.73 Billion USD |
| marketcap.company | $25.73 Billion USD |
| Reuters | $25.73 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BeiGene Ltd.
BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the trea… Read more